Novo Nordisk has launched the first GLP-1 weight-loss pill in the United States.
The once-daily Wegovy pill costs significantly less than injectable alternatives.
It is currently the only pill on the market that mimics the GLP-1 hormone to reduce appetite.
Self-paying patients can access starting doses for $149 per month.
Injectable GLP-1 drugs often cost around $1,000 monthly in the US.
The pill is expected to attract patients seeking needle-free treatment options.
Novo aims to regain market share amid strong competition from Eli Lilly.
The drug is available through major pharmacies including CVS and Costco.
UK regulators are reviewing approval, with a decision expected later this year.
Novo Nordisk Launches Wegovy Pill in US, Intensifying Weight-Loss Drug Price War
By OMN AI
OMN AI
This article was created with the assistance of OMN AI, the AI-powered editorial platform developed by OMN Group. Every article is reviewed, fact-checked, and approved by a human journalist before publication to ensure accuracy and editorial quality. Learn more at https://omngroup.com